CY1119789T1 - Cgrp αντισωματα - Google Patents

Cgrp αντισωματα

Info

Publication number
CY1119789T1
CY1119789T1 CY20181100064T CY181100064T CY1119789T1 CY 1119789 T1 CY1119789 T1 CY 1119789T1 CY 20181100064 T CY20181100064 T CY 20181100064T CY 181100064 T CY181100064 T CY 181100064T CY 1119789 T1 CY1119789 T1 CY 1119789T1
Authority
CY
Cyprus
Prior art keywords
cgrp antibodies
genetically engineered
binding fragments
present
related peptide
Prior art date
Application number
CY20181100064T
Other languages
English (en)
Inventor
Barrett Allan
Robert Jan Benschop
Mark Geoffrey Chambers
Ryan James Darling
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1119789T1 publication Critical patent/CY1119789T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ανθρώπινα δημιουργημένα με γενετική μηχανική αντισώματα πεπτιδίου σχετιζόμενου με το γονίδιο καλσιτονίνης (CGRP) ή θραύσματα πρόσδεσης αντιγόνου αυτών. Επιπλέον, η παρούσα εφεύρεση παρέχει τη χρήση των ανθρώπινων δημιουργημένων με γενετική μηχανική αντισωμάτων πεπτιδίου σχετιζόμενου με το γονίδιο καλσιτονίνης (CGRP) ή θραυσμάτων πρόσδεσης αντιγόνου αυτών για την αντιμετώπιση πόνου οστεοαρθρίτιδας.
CY20181100064T 2010-06-10 2018-01-18 Cgrp αντισωματα CY1119789T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35332310P 2010-06-10 2010-06-10
PCT/US2011/039381 WO2011156324A1 (en) 2010-06-10 2011-06-07 Cgrp antibodies

Publications (1)

Publication Number Publication Date
CY1119789T1 true CY1119789T1 (el) 2018-06-27

Family

ID=45096388

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100064T CY1119789T1 (el) 2010-06-10 2018-01-18 Cgrp αντισωματα
CY2019017C CY2019017I2 (el) 2010-06-10 2019-04-02 Cgrp αντισωματα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2019017C CY2019017I2 (el) 2010-06-10 2019-04-02 Cgrp αντισωματα

Country Status (34)

Country Link
US (3) US9073991B2 (el)
EP (2) EP2579894B1 (el)
JP (2) JP6021806B2 (el)
KR (1) KR101489566B1 (el)
CN (2) CN104292332B (el)
AR (1) AR081434A1 (el)
AU (1) AU2011265050B2 (el)
BR (1) BR112012031501B1 (el)
CA (1) CA2802102C (el)
CY (2) CY1119789T1 (el)
DK (1) DK2579894T3 (el)
EA (1) EA022931B1 (el)
ES (2) ES2656000T3 (el)
HK (1) HK1203211A1 (el)
HR (1) HRP20171992T1 (el)
HU (2) HUE038135T2 (el)
IL (2) IL222885B (el)
JO (1) JO3330B1 (el)
LT (2) LT2579894T (el)
LU (1) LUC00112I2 (el)
ME (1) ME02862B (el)
MX (2) MX363209B (el)
NL (1) NL300979I2 (el)
NO (2) NO2579894T3 (el)
NZ (1) NZ603607A (el)
PL (1) PL2579894T3 (el)
PT (1) PT2579894T (el)
RS (1) RS56638B1 (el)
SG (1) SG185648A1 (el)
SI (1) SI2579894T1 (el)
TW (1) TWI423818B (el)
UA (1) UA109658C2 (el)
WO (1) WO2011156324A1 (el)
ZA (1) ZA201208996B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57194B1 (sr) 2005-11-14 2018-07-31 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje
MX2010009722A (es) 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
EP3165236B1 (en) 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
LT3495392T (lt) * 2011-05-20 2021-09-27 H. Lundbeck A/S Anti-cgrp kompozicijos ir jų panaudojimas
NZ732875A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
EP2888283B1 (en) 2012-08-24 2018-09-19 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
MD20170055A2 (ro) 2014-10-24 2017-09-30 Merck Sharp & Dohme Corp Co-agonişti ai receptorilor glucagonului şi GLP-1
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
KR20180054851A (ko) * 2015-10-30 2018-05-24 일라이 릴리 앤드 캄파니 항-cgrp/항-il-23 이중특이적 항체 및 그의 용도
CN105483091A (zh) * 2015-12-29 2016-04-13 天津三箭生物技术股份有限公司 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
KR20180091930A (ko) * 2016-01-28 2018-08-16 일라이 릴리 앤드 캄파니 Cgrp 항체 및 그의 용도
US11492386B2 (en) 2016-02-01 2022-11-08 Eli Lilly And Company Parathyroid hormone-anti-RANKL antibody fusion compounds
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
EP3515488A1 (en) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Treating cluster headache
BR112019005823A2 (pt) 2016-09-23 2019-06-25 Teva Pharmaceuticals Int Gmbh tratamento para enxaqueca refratária
JP7195262B2 (ja) 2017-03-02 2022-12-23 ベス イスラエル デアコネス メディカル センター インコーポレイティッド カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法
AR111845A1 (es) 2017-05-03 2019-08-28 Lilly Co Eli Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
CA3066893A1 (en) * 2017-06-21 2018-12-27 Cephalon, Inc. Cation exchange chromatography wash buffer
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
CA3087951A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
WO2019231800A1 (en) 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
MA53436A (fr) 2018-08-22 2021-12-01 Lilly Co Eli Anticorps anti-cgrp pour patients résistants au traitement
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies
EP3744400A1 (en) * 2019-05-28 2020-12-02 Etablissement Français du Sang Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml)
WO2020239014A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 抗cgrp抗体及其应用
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
US20240139171A1 (en) 2021-03-02 2024-05-02 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN117586390A (zh) * 2022-08-11 2024-02-23 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1992019759A1 (en) * 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
JP4976376B2 (ja) 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
RS57194B1 (sr) * 2005-11-14 2018-07-31 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
EP2265288B1 (en) * 2008-03-04 2016-05-11 Labrys Biologics Inc. Methods of treating inflammatory pain
MX2010009722A (es) * 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo

Also Published As

Publication number Publication date
CA2802102C (en) 2016-07-26
RS56638B1 (sr) 2018-03-30
KR20130034024A (ko) 2013-04-04
PT2579894T (pt) 2018-02-06
SG185648A1 (en) 2012-12-28
US20110305711A1 (en) 2011-12-15
HRP20171992T1 (hr) 2018-02-09
AU2011265050B2 (en) 2013-06-27
EP3318272B1 (en) 2022-08-10
KR101489566B1 (ko) 2015-02-03
NO2019017I1 (no) 2019-04-05
CN104292332B (zh) 2019-11-01
BR112012031501A2 (pt) 2016-10-25
LUC00112I1 (el) 2019-04-10
AU2011265050A1 (en) 2012-11-08
US20150259415A1 (en) 2015-09-17
CN104292332A (zh) 2015-01-21
HK1203211A1 (en) 2015-10-23
EP2579894A1 (en) 2013-04-17
JP2013532143A (ja) 2013-08-15
EA201270769A1 (ru) 2013-04-30
TW201210618A (en) 2012-03-16
EP2579894A4 (en) 2013-12-04
LTPA2019011I1 (lt) 2019-05-10
NL300979I2 (nl) 2019-07-11
WO2011156324A1 (en) 2011-12-15
HUS1900020I1 (hu) 2019-05-28
CN102946905B (zh) 2014-10-15
NZ603607A (en) 2014-09-26
TWI423818B (zh) 2014-01-21
BR112012031501B1 (pt) 2020-02-11
JP2017014203A (ja) 2017-01-19
PL2579894T3 (pl) 2018-04-30
EA022931B1 (ru) 2016-03-31
LT2579894T (lt) 2018-02-26
HUE038135T2 (hu) 2018-09-28
JO3330B1 (ar) 2019-03-13
MX2012014480A (es) 2013-02-07
US9073991B2 (en) 2015-07-07
IL222885B (en) 2019-09-26
IL242409B (en) 2020-07-30
AR081434A1 (es) 2012-08-29
CA2802102A1 (en) 2011-12-15
CY2019017I1 (el) 2020-05-29
IL222885A0 (en) 2012-12-31
CN102946905A (zh) 2013-02-27
NL300979I1 (nl) 2019-04-17
MX340999B (es) 2016-08-03
SI2579894T1 (en) 2018-01-31
MX363209B (es) 2019-03-14
ES2930321T3 (es) 2022-12-09
ME02862B (me) 2018-04-20
JP6021806B2 (ja) 2016-11-09
UA109658C2 (xx) 2015-09-25
ZA201208996B (en) 2014-05-28
LTC2579894I2 (lt) 2020-03-25
CY2019017I2 (el) 2020-05-29
LUC00112I2 (el) 2019-12-27
ES2656000T3 (es) 2018-02-22
EP3318272A1 (en) 2018-05-09
US20170073403A1 (en) 2017-03-16
EP2579894B1 (en) 2017-11-22
DK2579894T3 (en) 2018-01-15
US9505838B2 (en) 2016-11-29
JP6466883B2 (ja) 2019-02-06
NO2579894T3 (el) 2018-04-21

Similar Documents

Publication Publication Date Title
CY1119789T1 (el) Cgrp αντισωματα
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1122593T1 (el) Αντισωματα εναντι-cd40 και χρησεις αυτων
CY1123256T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
PH12018501554A1 (en) Ror1 antibody compositions and related methods
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
EA201891992A1 (ru) Химерные рецепторы и способы их применения
MX360295B (es) Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
CY1118200T1 (el) Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
UA117364C2 (uk) Похідні аматоксину
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
PH12017500890A1 (en) Antibody drug conjugates
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
CY1122132T1 (el) Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
MY166776A (en) Humanised anti-ctla4 antibodies